Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Wages, Salaries and Other
Others
Ratios

Candel Therapeutics (CADL) Profit After Tax (2020 - 2025)

Candel Therapeutics' Profit After Tax history spans 4 years, with the latest figure at -$11.1 million for Q4 2023.

  • On a quarterly basis, Profit After Tax fell 118.37% to -$11.1 million in Q4 2023 year-over-year; TTM through Dec 2023 was -$37.9 million, a 101.62% decrease, with the full-year FY2025 number at -$38.2 million, up 30.83% from a year prior.
  • Profit After Tax hit -$11.1 million in Q4 2023 for Candel Therapeutics, down from -$8.4 million in the prior quarter.
  • Over the last five years, Profit After Tax for CADL hit a ceiling of $1.6 million in Q4 2021 and a floor of -$17.1 million in Q2 2021.
  • Historically, Profit After Tax has averaged -$7.3 million across 4 years, with a median of -$8.4 million in 2023.
  • Biggest five-year swings in Profit After Tax: surged 115.23% in 2021 and later plummeted 877.22% in 2023.
  • Tracing CADL's Profit After Tax over 4 years: stood at -$10.5 million in 2020, then surged by 115.23% to $1.6 million in 2021, then plummeted by 418.48% to -$5.1 million in 2022, then crashed by 118.37% to -$11.1 million in 2023.
  • Business Quant data shows Profit After Tax for CADL at -$11.1 million in Q4 2023, -$8.4 million in Q3 2023, and -$9.6 million in Q2 2023.